Sporadic Thoughts: Aroung the Eearnings Block and Bargain Basement?

October 3-7 2005 – Minyanville.com Around the earnings block… Becton Dickenson (BDX) is another darling of mine that reported 3rd quarter numbers today. Revenues grew 8% (excluding currency benefit) and performance was very solid across all segments – a sign of business quality. BDX’s business lends itself to fairly good operational leverage, which was apparent…

October 3-7 2005 – Minyanville.com
Around the earnings block…

Becton Dickenson (BDX) is another darling of mine that reported 3rd quarter numbers today. Revenues grew 8% (excluding currency benefit) and performance was very solid across all segments – a sign of business quality. BDX’s business lends itself to fairly good operational leverage, which was apparent in this quarter’s performance as margins expanded, driving 20% EPS growth, INCLUDING stock based compensation EPS up 11.7% – still great performance. As I mentioned before, BDX is a good way to participate in rising healthcare spending without the risks and volatility that come with owning drug stocks.

On a less upbeat note, BJ Wholesale (BJ) reported mediocre (to say the least) 2.9% same store sales for October; the Street was expecting 5.1%. The company blamed results on a shift of Halloween into its November reporting period and Hurricane Wilma in Florida. Interestingly, Halloween and Wilma did not have the same impact on Costco (COST), which saw its same store sales up over 8% in the quarter. Were BJ’s customers the only ones that shifted their shopping into November? Though the company did not change its guidance and one month does not set a trend, I am putting BJ’s on a double secret probation.

Bargain basement?

Not yet According to the Financial Times, 48% of VNU shareholders oppose the VNU / IMS Health (RX) deal – Halellujah! As I mentioned in this article, we sold RX on the merger announcement, as merger of these loosely-related businesses made absolutely no sense. Though I am happy that deal is unlikely to be consummated, I’ll not be jumping into RX shares… unless RX visits a bargain basement price, and I have not determined what that may be yet. RX’s management lost a lot of credibility in my eyes and, more importantly, in the eyes of investors.

Vitaliy N. Katsenelson, CFA

Positions: BDX, BJ

Copyright Minyanville.com

This article is written for educational purposes only. It is not intended as a recommendation (or advice) to buy or sell securities. Author and/or his employer may have a position in the securities discussed in this article. Security positions may change at any time.

Please read the following important disclosure here.

Related Articles

Why I No Longer Mind Losing an Argument

Why I No Longer Mind Losing an Argument

Reflecting on my experience with Dale Carnegie's book, I share how it transformed my approach to criticism and debate, and why I no longer mind losing an argument.

How do I get any research done since I travel a lot?

I get asked at times: How do I get any research done since I travel a lot? To answer this question, I need to explain how we do research.
The Growing Pains of Maturity

The Growing Pains of Maturity

Many times, we bought because they were in their “junior year”; this is what made them undervalued. Our research led us to the conclusion that their difficulties were transitory and that as they matured the market would revalue them.
What is the Value of Apple? How do we evaluate risk?

What is the Value of Apple? How do we evaluate risk?

Today I will share the Q&A section of the letter. Every time I am almost finished with the client letter, I ask clients to send me any questions they have about their portfolio or other topics. I answer these questions in the Q&A section.

Leave a Comment